Compare KE & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KE | OVID |
|---|---|---|
| Founded | 1961 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 635.4M | 522.6M |
| IPO Year | 2014 | 2017 |
| Metric | KE | OVID |
|---|---|---|
| Price | $24.58 | $2.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $28.00 | $4.60 |
| AVG Volume (30 Days) | 128.5K | ★ 1.7M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $1,486,727,000.00 | $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.57 | $19.34 |
| P/E Ratio | $31.13 | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $17.56 | $0.27 |
| 52 Week High | $33.19 | $3.11 |
| Indicator | KE | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 42.00 |
| Support Level | $23.49 | $1.95 |
| Resistance Level | $26.92 | $2.72 |
| Average True Range (ATR) | 1.14 | 0.16 |
| MACD | -0.22 | -0.06 |
| Stochastic Oscillator | 29.48 | 20.45 |
Kimball Electronics Inc is a contract electronic manufacturing services company. The company is engaged in producing durable electronics for the automotive, medical, industrial, and public safety end markets. The company's engineering, manufacturing, and supply chain services utilize common production and support capabilities. It is also engaged in producing safety-critical electronic assemblies for its automotive customers. Geographically, it has business units located in the United States, China, Mexico, Poland, Romania, and Thailand. The company derives maximum revenue from Mexico.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.